MinterEllison has assisted BARD1 Life Sciences Limited (BD1) on its institutional placement and share purchase plan, which are expected to raise a total of approximately $17 million.

The capital raising will help fund BARD1's further development and commercialisation of SubB2M tests for ovarian and breast cancer, commercialisation of EXO-NET products and other critical research.

MinterEllison was delighted to support BARD1 in the capital raising, which incorporated a number of components, including the offer of free attaching options to participants in the placement and the share purchase plan on the basis of one option for every two shares issued, which will be offered together with the share purchase plan under a prospectus.

"We are pleased to have assisted BARD1 Life Sciences in this capital raising to support their important work. This raising will further BARD1's life saving cancer research and product development. It provides both new and existing investors with the opportunity to invest in critical medical research and development," said Partner Sudharshan Senathirajah.

MinterEllison and Kidder Williams (as financial adviser to BARD1) have worked together and supported BD1 on a number of recent transactions, including acting on its acquisition of Sienna Cancer Diagnostics Limited last year.

The MinterEllison team working with BARD1 comprised Bart Oude-Vrielink, Sudharshan Senathirajah, Alexander Persano and Josh Carfi.